

CONFERENCE PROGRAM As at 14 August 2023 Draft subject to change without notice

THURSDAY 17 AUGUST 2023

1600-1830 Registration Open, M15 (Mezzanine Level)

¹⁸⁴⁵⁻²²⁰⁰ International Faculty Dinner (Invitation Only), Cairns Regional Art Gallery

18 AUGUST 2023
Registration Open, M15 (Mezzanine Level)
Industry Exhibition Open, Mezzanine Level Foyer and Plenary Room 1 (Mezzanine Level)
Multidisciplinary Plenary
Trinity Room (Trinity Level)
Professor Tony Costello & Dr Phil Dundee
Conference Opening
Patrick C Walsh Lecture: How anatomy continues to instruct the surgeon for improvements in post prostatectomy continence Professor Kirsten Greene
Presentation 1: Emerging role of precision medicine in prostate cancer management Professor Leonard Gomella
Presentation 2: The utility of AI in selecting patients that benefit from ADT Professor Daniel Spratt
Knowing the Literature: Diagnostics - Focal Therapy/Active Surveillance Papers - Overview of current papers in prostate cancer from a global pers Professor Henry Woo
MDT Panel
Screening, investigation and treatment of early stage prostate cancer The diagnostic and treatment algorithm for early stage, screen detected prostate cancer has changed considerably in the past 10 years. The introduction biopsy, PSMA PET/CT and genomic screening has led to a more sophisticated investigation pathway and allowed the expansion of active surveillance management of some patients with intermediate risk prostate cancer. This MDT will focus on the diagnostic and management conundrums of early <i>Professor Leonard Gomella (Urologist/Genomics), Professor Daniel Spratt (Radiation Oncologist), Dr Peter Swindle (Urologist) and Professor Henry Kirsten Greene (Urologist), Associate Professor Niall Corcoran (Urologist)</i> Chaired by Dr Phil Dundee

erspective

roduction of MRI, transperineal ance to incorporate the rly stage prostate cancer. nry Woo (Urologist), Professor

1100-1230	Concurrent Session 1A		Concurrent Session 1B		Concurrent Sess
Theme	Clinical Urology Diagnostics	Theme	Nursing & Allied Health Navigating Prostate Cancer Care: Advances in the Frontier	Theme	Radiation Oncolo Radiation Oncology and artificial intellig Sponsored by Ge LifeHealthcare
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)	Room	Meeting Room M
Chairs	Dr Fairleigh Reeves & Professor Henry Woo	Chairs	Ms Rachel Heerey & Ms Evie Mertens	Chairs	Dr Mario Guerrie
1100-1120	Incorporating AI into the diagnostic algorithm Dr Peter Swindle	1100-1115	Pushing the limits of active surveillance A/Professor Niall Corcoran	1100-1120	The future of Al primetime? Professor Daniel
1120-1140	Genomics and risk stratification in prostate cancer Professor Leonard Gomella	1115-1130	The latest in penile rehabilitation protocols Professor Arthur Burnett	1120-1140	Prostate brachyt Professor Peter (
1140-1200	PSMA PET/CT for prostate cancer diagnosis and primary staging Professor Louise Emmett	1130-1145	Radiation oncology in 2023 - What's New A/Professor Michael Ng	1140-1200	Post prostatector Professor Michae
1200-1220	Update on PSA screening Guidelines A/Professor David Smith	1145-1200	Innovations in Prostate cancer related incontinence Professor Paul Hodges	1200-1220	MRI linac and fut Dr Timothy Squii
1220-1230	Q&A and Discussion	1200-1215	Advances in nursing research Dr Natasha Roberts	1220-1230	Q&A and Discuss
		1215-1230	Advances in psycho-oncology: implementing new findings into clinical practice <i>Professor Chris Nelson</i>		

ession 1C

ology gy 2023 - Integrating advanced imaging lligence for improved outcomes GenesisCare and e Pty Ltd

M11 (Mezzanine Level)

rieri & Professor Michael Chao

Al in prostate cancer. Ready for

el Spratt

ytherapy for higher risk disease ⁻ Orio

tomy rectal spacer ael Chao

uture directions uire

ssion

1330-1530	Concurrent Session 2A		Concurrent Session 2B		Concurrent Sess
Theme	Clinical Urology Active surveillance	Theme	Nursing & Allied Health Thriving Beyond A Prostate Cancer Diagnosis: Evidence Based Practice in Survivorship	Theme	Radiation Oncolo Radiation Oncology and artificial intellig Sponsored by Ge LifeHealthcare
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)	Room	Meeting Room M ²
Chairs	Dr Briony Norris & Dr Justin Peters	Chairs	Professor Daniel Galvao & Ms Rachel Oxford- Webb	Chairs	Dr Mario Guerrie
1330-1350	Can genomics assist in selecting patients for AS? Professor Leonard Gomella	1330-1345	Survivorship on the global stage Professor Suzanne Chambers	1330-1350	The utility of pos scanning in radio A/Professor Mich
1350-1410	Which intermediate risk patients should <i>not</i> be offered AS? A/Professor Niall Corcoran	1345-1400	NHMRC Centre of Research Excellence - prostate cancer survivorship update Professor Suzanne Chambers	1350-1410	The use of the M Dr Jeremy De Le
1410-1430	How do we manage intermediate risk: AS protocols for surveillance and triggers for treatment Dr Fairleigh Reeves	1400-1410	Survivorship essentials framework translational projects A/Professor Nicole Heneka & Dr Anna Green	1410-1430	Radiation prescri on radiotherapy Daniel Papworth
1430-1450	The role of imaging in patient selection and surveillance in AS Professor Henry Woo	1410-1420	What's new in exercise and prostate cancer <i>Professor Daniel Galvao</i>	1430-1450	An update of the Dr Sarat Chander
1450-1510	Assessing psychological impact of patients on active surveillance <i>Professor Chris Nelson</i>	1420-1430	Mapping prostate cancer care pathways A/Professor Nicole Heneka & Isabelle Schaefer	1450-1510	The next version beyond Dr Eric Wegener
1510-1530	Q&A and Discussion	1430-1440	Vanguard approach to specialist nurse-led survivorship care <i>Ms Sally Sara</i>	1510-1530	Q&A and Discussi
		1440-1450	Panel Q&A and Discussion]	
		1450-1530	Rapid Fire Abstract Presentations		

ssion 2C

blogy gy 2023 - Integrating advanced imaging lligence for improved outcomes GenesisCare and e Pty Ltd

M11 (Mezzanine Level) rieri & A/Professor Amy Hayden

oost prostatectomy PSMA PET liotherapy decision making ichael Ng

MRI linac in prostate cancer Leon

cription trends and the impact by workflows th

he HDR boost data der

on of Prostate SABR: 2023 and

?r

ssion

1600-1730	Concurrent Session 3A		Concurrent Session 3B		Concurrent Sess
Theme	Clinical Urology What's new in prostate cancer treatment	Theme	Nursing & Allied Health Connection and Communication in Cancer Care	Theme	Theranostics Workshop: Theranos treatment of prostat Sponsored by Te
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)	Room	Meeting Room M
Chairs	A/Professor Niall Corcoran & Dr Jinna Yao	Chairs	Mr Max Rutherford & Ms Shan Morrison	Chairs	Professor Rod H
1600-1620	Emerging technologies - a look into the future Professor Jeff Caddedu	1600-1615	Patient Story	1600-1620	Current strategie RLT Professor Rod Hiv
1620-1635	Novel therapeutics in prostate cancer Professor Oliver Sartor	1615-1635	The language of cancer Mr Tim Baker	1620-1640	Where next? Nov Australian Perspe A/Professor Shah
1635-1650	ProFocal - a cooled focal laser therapy system for prostate cancer ablation. Results of the phase one Australian trial <i>A</i> / <i>Professor Celi Varo</i>	1635-1655	A low intensity approach to psychological care for men with prostate cancer <i>Professor Suzanne Chambers</i>	1640-1700	Novel radiopharn Professor Nat Lei
1650-1705	Prostate brachytherapy: can it be used as a focal treatment in the primary and salvage settings <i>Professor Peter Orio</i>	1655-1715	Identifying the unidentified distress of prostate cancer - who's role is this? Ms Melissa Martin		Complementary radiotherapy in t radiouclide thera Dr Paul Conway
1705-1725	High dose testosterone in treating prostate cancer: Where are we now? <i>Professor Oliver Sartor</i>	1715-1730	Panel Discussion Professor Suzanne Chambers, Mr Tim Baker, Ms Melissa Martin, Mr Max Rutherford	1720-1730	Q&A and Discussi
1725-1730	Q&A and Discussion				
1745-1900	Welcome Reception, Industry Exhibition (Mezzanine Leve	el Foyer an	d Plenary Room 1), Cairns Convention Centre	9	
1900-2130	Satellite Dinner Meetings				
Theme	Clinical Urology		Nursing and Allied Health		
Room	Plenary Room 2 (Mezzanine Level)		Meeting Rooms M9&10 (Mezzanine Level)		
Chair	Dr Phil Dundee		Eveline Mertens		
Description	Flip the script: who should prescribe novel AR inhibitors		The Evolution of Prostate Cancer Supportive Care over the past 20 years Ms Helen Crowe AM, Ms Shan Morrison, Professor Rob Newton and Ms Ka		

ssion 3C

nostics - Is it a game changer in the state cancer? **Telix Pharmaceuticals**

M11 (Mezzanine Level) Hicks & Professor Nat Lenzo

gies for selection of patients for

Hicks

ovel combination trials an spective *andneen Sandhu*

rmaceuticals

enzo

y role of stereotactic In the context of systemic erapy

ssion

ay Talbot

SATURD	AY 19 AUGUST 2023
0645-1730	Registration Open, M15 (Mezzanine Level)
0700-0815	Breakfast Session: Life Lessons from the Depths with Tim Baker and Max Rutherford
	Mr Tim Baker & Mr Max Rutherford
	Chaired by Mr Marc Diocera
	Sponsored by Mundipharma
Room	Meeting Rooms M9&10 (Mezzanine Level)
0800-1730	Industry Exhibition Open, Mezzanine Level Foyer and Plenary Room 1 (Mezzanine Level)
0830-1030	Multidisciplinary Plenary
Room	Trinity Room (Trinity Level)
Chairs	A/Professor Daniel Moon & A/Professor Janelle Brennan
0830-0850	Presentation 1: A strategy to decrease deaths from prostate cancer
	Professor Chris Sweeney
0850-0910	Presentation 2: Changing landscape in mHSPC
	A/Professor Alicia Morgans
0910-0930	Presentation 3: What's wrong with prostate cancer treatments today
	Professor Oliver Sartor
0930-0940	Q&A and Discussion
0940-1000	Knowing the Literature: Hormone sensitive metastatic disease - Overview of current papers in prostate cancer from a global perspective
	A/Professor Ben Tran
1000-1030	MDT Panel
	An MDT approach to patient management in mHSPC
	The mHSPC treatment landscape has rapidly evolved with newer therapies such as novel hormonal agents and needing to define which patients benefit from radiation to the
	prostate or addition of docetaxel. Hearing from the multi-disciplinary teams, this panel will explore different areas of patient management in mHSPC and how to match the
	right patient to the right therapy using PSMA-PET-CT imaging. Professor Louise Emmett (Clinical Researcher Nuclear Medicine & Theranostics), Dr Roger Watson (Urologist), A/Professor Jeff Goh (Medical Oncologist), Professor Chris
	Nelson (Psychologist), Mr Marco Hake (Nurse Practitioner) & Professor Daniel Galvao (Exercise Physiologist)
	Chaired by Professor Chris Sweeney
	Sponsored by Janssen
1030-1100	Morning Tea & Industry Exhibition, Mezzanine Level Foyer and Plenary Room 1 (Mezzanine Level)

1100-1300	Concurrent Session 4A		Concurrent Session 4B	Ň
Theme	Clinical Urology High Risk localised and N1 Disease	Theme	Nursing & Allied Health Tackling the Hard Problem: managing sexual dysfunction in patients with prostate cancer Sponsored by Endotherapeutics and VacuMED Pty Ltd	١
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)	
Chairs	Dr Phil Dundee & Associate Professor Amy Hayden	Chairs	Ms Evie Mertens & Ms Francesca Rogers	
1100-1120	How I manage patients with clinically node positive disease - US perspective <i>Professor Kirsten Greene</i>	1100-1110	Introduction & Device Demonstration Ms Francesca Rogers	
1120-1140	How I manage patients with clinically node positive disease - Australian perspective A/Professor John Yaxley	1110-1135	Is any intimacy possible after prostate cancer treatment? Professor Chris Nelson	
1140-1200	How I manage patients with clinically node positive disease - Radiation Oncologist perspective <i>Professor Daniel Spratt</i>	1135-1200	Current and future approaches for managing erectile dysfunction after radical prostatectomy <i>Professor Arthur Burnett</i>	
1200-1220	Known outcomes of patients clinical pelvic node positive disease in the ICECaP database: How can we do better? <i>Professor Chris Sweeney</i>	1200-1210	Sexual function consultation in gay men with prostate cancer: An ally's perspective on best strategies <i>Professor Chris Nelson</i>	
1220-1240	Management of high risk prostate cancer Dr Jinna Yao	1210-1230	Putting theory into practice: interesting cases Ms Francesca Rogers	
1240-1300	Q&A and Discussion	1230-1240	Couples interventions to increase intimacy following prostate cancer treatment Professor Chris Nelson	
		1240-1255	Realities of penile prosthesis - the patient experience <i>Ms Kay Talbot</i>	
		1255-1300	Q&A	

10	Session	
	<u> </u>	

No Session

hia

1400-1530	Concurrent Session 5A		Concurrent Session 5B	N
Theme	Clinical Urology mHSPC	Theme	Nursing & Allied Health Going with the Flow: Overcoming continence challenges in prostate cancer	N
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)	
Chairs	Dr Peter Swindle & Associate Professor Alicia Morgans	Chairs	Ms Shan Morrison & Ms Rachel Heerey	
1400-1420	The value of PSMA PET in metastatic prostate cancer Professor Louise Emmett	1400-1415	Potential bladder & bowel toxicities with radiation therapy <i>Ms Catherine White</i>	
1420-1435	Evolution of PET Imaging with Quadra Professor Rod Hicks	1415-1430	Best practice management of prostate cancer related incontinence Professor Paul Hodges	
1435-1455	Practical approach to prescribing in mHSPC in Australia A/Professor <i>Ben Tran</i>	1430-1445	Medical and surgical management of post treatment incontinence Dr Jodi Hirst	
1455-1515	Making further advances in mHSPC with the BSPOKE-CaP Platform Professor Chris Sweeney	1445-1500	The Four Cs: Continence, Clamps, Cuffs & Containment Mr Michael Cromer	
1515-1530	Q&A and Discussion	1500-1515	Applying best practice to the clinical consultation - case studies Ms Shan Morrison	
		1515-1530	Q&A and Discussion	
1530-1600	Afternoon Tea & Industry Exhibition, Mezzanine Level Fo	oyer and Ple	enary Room 1 (Mezzanine Level)	

No Session
No session

1600-1730	Concurrent Session 6A		Concurrent Session 6B - Workshop		Concurrent Sess
Theme	Clinical Urology Cancer recurrence	Theme	Nursing & Allied Health Workshop Androgen Deprivation Therapy: A deep dive into everything you need to know Sponsored by AstraZeneca	Theme	Nursing & Allied Tackling the Hard P in patients with pro Sponsored by El VacuMED Pty Lt
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)	Room	Meeting Room M
Chairs	Dr Mario Guerrieri & Associate Professor Joseph Ischia	Chairs	Ms Molly Lowther & Mr Marc Diocera	Chairs	Ms Francesca Rog Webb
1600-1620	Salvage options for recurrence following prostatectomy Dr Mario Guerrieri	1600-1620	What is ADT? Professor Alicia Morgans	1600-1610	Introduction Ms Francesca Rog
1620-1640	Salvage options for recurrence following radiotherapy Professor Phillip Stricker	1620-1710	Rotating small group workshop and hands on demonstrations and discussions with facilitator/s, covering injection tips and	1610-1730	Facilitator with s topics such as pe medication, inte
1640-1700	Metastasis directed therapy - patient selection and incorporation of ADT <i>Professor Daniel Spratt</i>		tricks, outcome measures, care plans, psychology, exercise interventions, and patient resources		intimacy strateg
1700-1720	Rectal spacing in men undergoing prostate radiotherapy: past, present and future <i>Professor Peter Orio</i>				
1720-1730	Q&A and Discussion	1710-1730	ADT Survivorship: putting it all together. One Model of an ADT Survivorship Clinic. Dr Jane Crowe, Ms Molly Lowther, Ms Helen Crowe AM		
1730-1900	Free Time	•	·		<u> </u>
1900-2330	Conference Celebration Event, Boardwalk Social, Crystal	lbrook - Elvr			

ssion 6C - Workshop

ed Health Workshop

Problem: managing sexual dysfunction rostate cancer

Endotherapeutics and Ltd

M11 (Mezzanine Level)

Rogers & Ms Rachel Oxford-

Rogers

h group discussions covering penile rehabilitation regimes, tercavernosal injections, pumps, egies, toys and peyronies

0800-1400	Registration Open, M15 (Mezzanine Level)
0800-1530	Industry Exhibition Open, Mezzanine Level Foyer and Plenary Room 1 (Mezzanine Level)
0830-1030	Multidisciplinary Plenary
Room	Trinity Room (Trinity Level)
Chairs	A/Professor John Yaxley & Professor Daniel Spratt
0830-0850	Presentation 1: Consideration for sequencing treatment in mCRPC A/Professor Alicia Morgans
0850-0910	Presentation 2: Evidence for PSMA theranostics - The Australian TheraP trial Professor Louise Emmett
0910-0930	Presentation 3: LuPSMA: Updates and future considerations/Evidence for PSMA theranostics - The International Vision Trial <i>Professor Oliver Sartor</i>
0930-0940	Q&A and Discussion
0940-1000	Knowing the Literature: Advanced Disease - Overview of current papers in prostate cancer from a global perspective <i>Professor Oliver Sartor</i>
1000-1030	MDT Panel
	Advanced Disease & Survivorship Management of locally advanced prostate cancer has been evolving over the last decade. We will explore the increasing role of surgery for clinical local control in this cohort and review new radiation oncology techniques, including dose escalation via a brachytherapy boost or hypo-fractionated image guided external beam radiation. The MDT will also explore the management of locally advanced disease associated with pelvic lymph node only metastases on staging PSMA PET scan at diagnosis. <i>Professor Kirsten Greene (Urologist), Professor Daniel Spratt (Radiation Oncologist), Professor Chris Nelson</i> <i>(Psychologist), A/Professor Daniel Moon (Urologist), Dr Mario Guerrieri (Radiation Oncologist) & Ms Sally Sara</i> <i>(Urology Nurse)</i> <i>Chaired by A/Professor John Yaxley and Dr Peter Swindle</i> <i>Sponsored by AstraZeneca</i>

1100-1230	Concurrent Session 7A		Concurrent Session 7B
Theme	Clinical Urology Metastatic prostate cancer	Theme	Nursing & Allied Health Jigsaw: Piecing together the advanced prostate cancer landscape
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)
Chairs	Prof Chris Sweeney & Professor Kirsten Greene	Chairs	Mr Marc Diocera & Ms Rachel Oxford-Webb
1100-1120	Is PROTECT practice changing? A/Professor John Yaxley	1100-1120	Germline genomics testing for non geneticists - why and how? Dr Jane Crowe
1120-1140	Testosterone replacement in prostate cancer survivors with testosterone deficiency <i>Professor Arthur Burnett</i>	1120-1140	Exercise oncology management of patients with metastatic prostate cancer <i>Professor Rob Newton</i>
1140-1200	Prostate cancer and inherited risk Professor Leonard Gomella	1140-1200	The patient journey - prostate cancer and theranostics <i>Ms Katherine Lyons</i>
1200-1220	Is there a role of SBRT for oligoprogressive mCRPC A/Professor Amy Hayden	1200-1220	Big picture, small pieces: putting together resources in advanced prostate cancer survivorship <i>Mr Marc Diocera</i>
1220-1230	Q&A discussion and Announcement of Poster Award	1220-1230	Q&A

1230-1330	Rapid Fire Poster Presentations, Plenary Room 1 (Mezzanine Level) Moderators by A/Professor Ben Tran & Dr		
Theme	Clinical Urology Functional Outcomes and Survivorship	Theme	Nursing & Allied Health Living fully until the end: the role of palliative care in prostate cancer
Room	Trinity Room (Trinity Level)	Room	Meeting Rooms M9&10 (Mezzanine Level)
Chairs	Dr Justin Peters & A/Professor Troy Gianduzzo	Chairs	Ms Sally Sara & A/Professor Nicole Heneka
1330-1350	Current and future approaches managing ED after radical prostatectomy Professor Arthur Burnett	1330-1400	Understanding death and dying from prostate cancer and optimising end of life care <i>Ms Anne Joyce</i>
1350-1410	Functional evaluation of the pelvic floor to guide individualised management <i>Professor Paul Hodges</i>	1400-1420	Small Changes, Big Gains - techniques for effective communication in palliative care Ms Margaret Shearer & Ms Cas McIntyre
1410-1430	Exercise medicine as neoadjuvant, adjuvant and rehabilitative therapy for prostate cancer <i>Professor Rob Newton</i>	1420-1440	Voluntary assisted dying Dr Cameron McLaren
1430-1450	Standardised care pathways for prostatectomy and regionalisation <i>Professor Kirsten Greene</i>	1440-1500	Patient Story
1450-1510	The cognitive effects of hormone therapy Professor Chris Nelson	1500-1525	Q&A and Discussion
	OC Land Discussion	1525-1530	Conference Closing
1510-1520	Q&A and Discussion	1525 1550	